The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient’s bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees.

Key Features:

• Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents

• Contains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationales

• Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalities

• Thoroughly updated and revised chapters cover new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicities

• Discusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments

• Provides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach